| DOTMP | 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid |
| TCMC/DOTAM | 2-[4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetamide |
| DOTP | 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetra(methylene phosphonic) acid |
| BAPTA | 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid |
| cyclen | 1,4,7,10-tetraazacyclododecane |
| DOTA | 2,2′,2″,2‴-(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid |
| NOTA | 2,2′,2″-(1,4,7-triazacyclononane-1,4,7-triyl)triacetic acid |
| HEHA | 1,4,7,10,13,16-hexaazacyclooctadecane-N,N′,N″,N‴,N⁗,N″‴-hexaacetic acid |
| TETA | 1,4,8,11-Tetraazacyclotetradecane-1,4,8,11-tetraacetic acid |
| EDTMP | {Ethane-1,2-diylbis[nitrilobis(methylene)]}tetrakis(phosphonic acid) |
| NETA | {4-[2-(bis-carboxy-methylamino)-5-(4-nitrophenyl)pentyl]-7-carbo-xymethyl-[1,4,7]triazanonan-1-yl} acetic acid |
| p-SCN-Bn-TCMC | S-2-(4-Isothiocyanatobenzyl)-1,4,7,10-tetraaza-1,4,7,10-tetra(2-carbamoylmethyl)cyclododecane |
| DO3AM | 2,2′,2″-(1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetamide |
| DOTA-Re(Arg11)CCMSH | DOTA-Re(Arg11)(Cys3,4,10,d-Phe7)-αMSH3-13 |
| PEPA | 1,4,7,10,13-pentaazacyclopentadecane-N,N′,N″,N‴,N⁗-pentaacetic acid |
| EDTA | Ethylenediaminetetraacetic acid |
| CHX-A″-DTPA | [(R)-2-Amino-3-(4-isothiocyanatophenyl)propyl]-trans-(S,S)-cyclohexane-1,2-diamine-pentaacetic acid |
| ACAC | Acetylacetone (Pentane-2,4-dione) |
| en | Ethylenediamine (Ethane-1,2-diamine) |
| C-NE3TA | 4-carboxymethyl-7-[2-(carboxymethyl-amino)-3-(4-nitro-phenyl)-propyl]-[1,4,7]triazonan-1-yl-acetic acid |
| DTPA | diethylenetriaminepentaacetic acid |
| AZEP-DTPA | cis-{2,7-bis-[bis-carboxymethyl-amino)-methyl]-azepan-1-yl}-acetic acid |
| NPTA | [{4-carboxymethyl-7-[2-(carboxymethylamino)-ethyl]-perhydro-1,4,7-triazonin-1-yl}-acetic acid |
| NETA | {4-[2-(bis(carboxymethyl)amino)ethyl]-7- carboxymethyl [1,4,7]triazonon-1-yl}-acetic acid |
| PIP-DTPA | cis-2,6-bis[N,N-bis(carboxymethyl)aminomethyl]-1-piperidineacetic acid |
| p-SCN-Bz-DOTA-GA | 2,2′,2″-(10-(1-carboxy-4-((4-isothiocyanatobenzyl)amino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid |
| EEDTA | Oxybis(ethylenenitrilo)tetraacetic acid (1,7-diaza-4-oxaheptane-l,l,7,7-tetra-acetic acid) |
| EGTA | ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (3,12-Bis(carboxymethyl)-6,9-dioxa-3,12-diazatetradecane-1,14-dioic acid) |
| L1 | 5-[2-(N-2-fluorenyl)ethylamino]-2,5,8-triaza [9]-2,6-pyridinophane |
| THP-cyclen | 1,1′,1″,1‴-(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayl) tetrakis(propan-2-ol) acid |
| VCAM1 | vascular cell adhesion molecule 1 |
| LP | Lone electron pair |
| REE | Rare earth elements |
| mAb | Monoclonal antibody |
| I.P. | intraperitoneal |
| I.V. | intravenous |
| RIT | Radioimmunotherapy |